期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 172, 期 -, 页码 148-182出版社
ELSEVIER
DOI: 10.1016/j.addr.2021.03.001
关键词
Cancer preclinical models; Nanotechnology; Cancer vaccine; Tumor immune microenvironment; Clinical translation
资金
- MultiNano@MBM project - Israeli Ministry of Health
- Fundacao para a Ciencia e Tecnologia-Ministerio da Ciencia, Tecnologia e Ensino Superior (FCT-MCTES) [ENMed/0051/2016]
- FCT-MCTES [SAICTPAC/0019/2015, SFRH/BD/131969/2017]
- la Caixa Foundation [LCF/PR/HR19/52160021, LCF/TR/CD20/52700005]
- European Research Council (ERC), PoC Grant [862580]
- ERC Advanced Grant [835227]
- Israel Science Foundation [1969/18]
- Melanoma Research Alliance [615808]
- Israel Cancer Research Fund (ICRF) Professorship award [PROF-18-682]
- Morris Kahn Foundation
- Rothschild Foundation (IL)
- European Research Council (ERC) [862580, 835227] Funding Source: European Research Council (ERC)
- Fundação para a Ciência e a Tecnologia [SFRH/BD/131969/2017, ENMed/0051/2016] Funding Source: FCT
Targeted immunotherapies have revolutionized cancer treatment, but tumor heterogeneity and immunosuppression mechanisms have hindered the success of cancer vaccines. Nanotechnology offers promising solutions, but the selection of appropriate preclinical models is crucial.
The remarkable success of targeted immunotherapies is revolutionizing cancer treatment. However, tumor heterogeneity and low immunogenicity, in addition to several tumor-associated immunosuppression mechanisms are among the major factors that have precluded the success of cancer vaccines as targeted cancer immunotherapies. The exciting outcomes obtained in patients upon the injection of tumor specific antigens and adjuvants intratumorally, reinvigorated interest in the use of nanotechnology to foster the delivery of vaccines to address cancer unmet needs. Thus, bridging nano-based vaccine platform development and predicted clinical outcomes the selection of the proper preclinical model will be fundamental. Preclinical models have revealed promising outcomes for cancer vaccines. However, only few cases were associated with clinical responses. This review addresses the major challenges related to the translation of cancer nano-based vaccines to the clinic, discussing the requirements for ex vivo and in vivo models of cancer to ensure the translation of preclinical success to patients. (c) 2021 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据